Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease ...

Positive immunogenicity and safety data from VLA15-221 Phase 2 study after second booster dose of Lyme disease vaccine candidate VLA15, showing strong immune response and favorable safety profile across all age groups.